Somatus, a Virginia-based healthcare company, is revolutionizing the way kidney disease is managed.
Founded in 2016 by Dr. Ikenna Okezie, the company has become a leader in value-based kidney care, prioritizing prevention and empowering patients to take control of their health.
Somatus identified a gap in traditional care, which often focuses on dialysis for late-stage kidney disease. Their model flips the script, emphasizing early detection and prevention. The company’s secret weapon? The proprietary RenalIQ platform. This AI-powered platform uses machine learning and analytics to track patient health, identify at-risk individuals, and offer telehealth and virtual care options.
Somatus further strengthens its approach through partnerships with local nephrologists, primary care physicians, and health plans. This multi-disciplinary approach ensures patients receive personalized, in-home care and the knowledge they need to manage their condition effectively.
In 2022, Somatus served over 150,000 members across various healthcare plans. That same year they secured over $325 million in Series E funding. This deal was ranked as one of the biggest healthcare VC deals of 2022, valuing the company at over $2.5 billion.
“Since our inception, Somatus has always been committed to bringing superior evidence-based integrated care to patients with kidney disease, which delays disease progression, improves quality of life, and lowers total cost of care,” Okezie said when announcing the Series E funding round. “This investment puts us in a great position to fund the expansion of our proven care model and continue building a nationwide network of providers and connected patients, who alongside our care teams are working together to improve lives and transform the industry.”
In June 2023, Somatus announced a significant expansion of their existing collaborative efforts with Kidney Care Center. This multi-state partnership leverages Somatus’s VBC (value-based care) model, Care Coordination (CKCC), and joint venture arrangements to enhance patient care through a local care team, advanced technology, and direct medical care.
Furthermore, Somatus signed the Health Evolution Pledge in October 2023, demonstrating their commitment to leveraging data to address health disparities and improve access to care in underserved communities.
In February 2024, Somatus was selected as a preferred partner by Sun Life U.S. to deliver a unique care model for their stop-loss members with late-stage kidney disease and heart disease. This collaboration aims to improve patient health outcomes while reducing costs through AI-driven medication management, care coordination, nutritional support, and transitions of care, aligning with Sun Life’s Clinical 360 program focused on data analytics to enhance outcomes.
With groundbreaking technologies and strategic partnerships, they offer hope to millions affected by CKD, promising a new era of compassionate healthcare. This impact is particularly significant given that over 37 million Americans have CKD, underscoring the potential of Somatus’s work.
